

YaleNewHaven**Health**  
**Smilow Cancer Hospital**

333 Cedar Street  
PO Box 208058  
New Haven, CT 06520-8058

Yale **CANCER  
CENTER**  
A Comprehensive Cancer Center Designated  
by the National Cancer Institute

NON-PROFIT ORG.  
U.S. POSTAGE  
**PAID**  
NEW HAVEN, CT  
PERMIT #526

**Center for Gastrointestinal Cancers  
at Smilow Cancer Hospital  
and Yale Cancer Center**

35 Park Street  
New Haven, CT 06511  
203.200.4422  
**[smilowcancerhospital.org](http://smilowcancerhospital.org)**

## Medical Oncologist, Dr. Raghav Sundar, Joins Center for Gastrointestinal Cancers



Raghav Sundar, MBBS, PhD  
*Associate Professor of Medicine (Medical Oncology)*

Appointments:  
203.200.4422

Email:  
[raghav.sundar@yale.edu](mailto:raghav.sundar@yale.edu)

Location:  
Smilow Cancer Hospital  
35 Park Street, NP4  
New Haven, CT 06511

Raghav Sundar, MBBS, PhD, is an Associate Professor of Medicine (Medical Oncology) and cares for patients with gastrointestinal malignancies including gastroesophageal, hepatobiliary, and colorectal cancer as part of the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center in New Haven. He received his Bachelor of Medicine, Bachelor of Surgery from the National University of Singapore where he also pursued his PhD. He underwent fellowship training at the Drug Development Unit, Royal Marsden Hospital, UK, and joins Yale from the National University Cancer Institute in Singapore.

Dr. Sundar specializes in experimental therapeutics and was part of a Phase 1 clinical trials team in Singapore where he was a Senior Consultant Medical Oncologist and

Research Director for the Department of Haematology-Oncology. His research interests are in biomarkers and therapeutic targets of gastroesophageal cancers and tumors that metastasize to the peritoneum, through multiomic profiling of the tumor microenvironment. Another area of interest is in chemotherapy induced peripheral neuropathy. His work has identified predictive biomarkers of systemic therapy in gastric cancer as well as potential novel therapeutic targets. He has published over 110 manuscripts in high impact journals such as *Cancer Discovery*, *Journal of Clinical Oncology*, *British Medical Journal*, *JAMA Oncology*, *Gastroenterology*, and *Gut*.